We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of Aleglitazar in Combination With Aspirin in Healthy Volunteers

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01188304
First Posted: August 25, 2010
Last Update Posted: November 2, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Hoffmann-La Roche
August 24, 2010
August 25, 2010
November 2, 2016
July 2010
October 2010   (Final data collection date for primary outcome measure)
To investigate the effect of aleglitazar in combination with aspirin on measured glomerular filtration rate [ Time Frame: 13 weeks ]
Same as current
Complete list of historical versions of study NCT01188304 on ClinicalTrials.gov Archive Site
  • To investigate the effect of aleglitazar in combination with aspirin on renal plasma flow, filtration fraction and estimated glomerular filtration rate [ Time Frame: 13 weeks ]
  • To investigate the effect of aleglitazar in combination with aspirin on renin-angiotensin system and on anti-diuretic hormone [ Time Frame: 13 weeks ]
  • To investigate the effect of aspirin in combination with aleglitazar on platelet function and serum thromboxane B2 [ Time Frame: 13 weeks ]
  • To investigate the pharmacokinetics of aleglitazar when co-administered with aspirin [ Time Frame: 13 weeks ]
  • To investigate safety and tolerability of aleglitazar [ Time Frame: 13 weeks ]
  • To investigate the effect of aleglitazar in combination with aspirin on electrolytes and osmolality clearances [ Time Frame: 13 weeks ]
Same as current
Not Provided
Not Provided
 
A Study of Aleglitazar in Combination With Aspirin in Healthy Volunteers
A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Investigate the Effect of 150 µg Aleglitazar Once Daily in Healthy Subjects Treated With 325 mg Aspirin Once Daily on Renal Function, Renin-angiotensin System and Platelet Aggregation
This randomized, double-blind, placebo-controlled, parallel group study will investigate the safety and tolerability, and the effect of aleglitazar in combination with aspirin on renal function, renin-angiotensin system and platelet aggregation in healthy volunteers. Volunteers will be randomized to receive daily doses of aleglitazar or placebo in combination with aspirin. The anticipated time on study drug is 5 weeks.
Not Provided
Interventional
Phase 1
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Healthy Volunteer
  • Drug: aleglitazar
    repeated daily doses
  • Drug: aspirin
    repeated daily doses
  • Drug: placebo
    repeated daily doses
  • Experimental: 1
    Interventions:
    • Drug: aleglitazar
    • Drug: aspirin
  • Placebo Comparator: 2
    Interventions:
    • Drug: aspirin
    • Drug: placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
44
October 2010
October 2010   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Healthy volunteers, aged 40 to 65 years inclusive
  • Body Mass Index (BMI) between 18 and 35 kg/m2 inclusive
  • Females of child-bearing potential must be willing to use two acceptable methods of contraception during the study and at least 3 months before start of the study
  • Non-smoker or currently smoking less than 5 cigarettes (or equivalent amount of other tobacco products) per day and is willing and able to stop smoking during the period in study center
  • Volunteer drinks no more than 3 cups of coffee, tea or soft drinks per day and is willing and able to stop drinking coffee, tea and soft drinks during the period in study center

Exclusion Criteria:

  • Any clinically relevant abnormal laboratory test results at screening
  • Volunteer has taken any prescribed, herbal or over-the-counter medication within 2 weeks prior to first dosing
  • A history of any clinical significant gastro-intestinal, cardiovascular, musculoskeletal, endocrine, hematological, psychiatric, renal, hepatic, bronchopulmonary or neurological conditions or lipid disorders
  • A positive test for human immunodeficiency virus (HIV-1 or HIV-2), hepatitis B or hepatitis C
  • History of intolerance to non-steroidal anti-inflammatory drugs (NSAIDs) or aspirin, history of gastric or duodenal ulceration, personal or family history of abnormal clotting or bleeding
Sexes Eligible for Study: All
40 Years to 65 Years   (Adult)
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT01188304
BP25329
Not Provided
Not Provided
Not Provided
Hoffmann-La Roche
Hoffmann-La Roche
Not Provided
Study Director: Clinical Trials Hoffmann-La Roche
Hoffmann-La Roche
November 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP